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Phosphoethanolamine modiﬁcation of lipid AAntimicrobial peptides (AMPs) play an important role as a host defense against microbial pathogens and are key
components of the human innate immune response. Neisseria meningitidis frequently colonizes the human
nasopharynx as a commensal but also is a worldwide cause of epidemic meningitis and rapidly fatal sepsis. In
the human respiratory tract, the only known reservoir ofN.meningitidis, meningococci are exposed to human en-
dogenous AMPs. Thus, it is not surprising that meningococci have evolved effective mechanisms to confer
intrinsic and high levels of resistance to the action of AMPs. This article reviews the current knowledge about
AMP resistance mechanisms employed by N. meningitidis. Two major resistance mechanisms employed by
meningococci are the constitutive modiﬁcation of the lipid A head groups of lipooligosaccharides by
phosphoethanolamine and the active efﬂux pump mediated excretion of AMPs. Other factors inﬂuencing AMP
resistance, such as the major porin PorB, the pilin biogenesis apparatus, and capsular polysaccharides, have
also been identiﬁed. Even with an inherently high intrinsic resistance, several AMP resistance determinants
can be further induced upon exposure to AMPs. Many well-characterized AMP resistance mechanisms in other
Gram-negative bacteria are not found inmeningococci. Thus,N.meningitidis utilizes a limited but highly effective
set of molecular mechanisms to mediate antimicrobial peptide resistance. This article is part of a Special Issue
entitled: Bacterial Resistance to Antimicrobial Peptides.
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Neisseria meningitidis, the meningococcus, is a Gram negative
aerobic encapsulated diplococcal β-proteobacterium. Meningococci
are carried asymptomatically by 5 to 10% of the overall population in
non-epidemic periods and are transmitted from a carrier by aerosol
droplets or respiratory secretions. N. meningitidis is unique among the
major bacterial agents of meningitis in that it causes epidemic as well
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meningococcal disease have occurred annually worldwide, with at least
50,000 deaths and as many survivors suffering neurological sequelae
[1]. The meningococcus causes a range of disease: rapid onset meningi-
tis and severe sepsis (meningococcemia), septic arthritis, pneumonia,
purulent pericarditis, conjunctivitis, otitis, sinusitis, and urethritis.
Meningococci are classiﬁed by serologic typing based on the biochemi-
cal composition of the capsular polysaccharides (serogroup), major
outer membrane porin proteins (serotype), other outer membrane
proteins (serosubtype), and lipooligosaccharide (immunotype). Of the
12 serogroups identiﬁed, almost all of invasive cases are caused by me-
ningococci that express one of six capsular polysaccharides (serogroups
A, B, C, X, Y, andW) andmost epidemic and endemic cases of meningo-
coccal disease are caused by a limited number of clonal groups deﬁned
genetically using multilocus sequence typing (MLST). The US licensed
vaccines against N. meningitidis are based on capsular polysaccharides
(CPS) with the more recent development of CPS-protein conjugate
vaccines for different combinations of serogroups A, C, Y and W [2–5].
New serogroup B vaccines using sub-capsular surface antigens are
now approved in the US, Europe, Australia and Canada.2. Antimicrobial peptides
Antimicrobial peptides play an important role in host defense
against microbial infection. In addition to being major components of
the innate immune response, AMPs also have many potential roles in
inﬂammatory responses by inducing the secretion of chemokines and
cytokines [6]. Antimicrobial peptides are peptides of 12–50 amino
acids with excess of basic amino acids (arginine, lysine and histidine),
thus resulting in a net positive charge (cationic). AMPs also generally
have signiﬁcant portion of hydrophobic amino acids residues and are
amphipathic to facilitate interaction with bacterial membranes. Based
on their structural characteristics, AMPs are classiﬁed into different cat-
egories [7]. Themost common classes are β-sheet peptides stabilized by
disulﬁde bonds such as β-defensins [8,9], and amphipathic α-helices
formed upon contact withmembranes such asα-defensins, cathelicidin
and LL-37 [10–12]. Less common are extended peptideswith a predom-
inance of one or two amino acids (e.g. proline, tryptophan or histidine)
and peptides with loop structures formed by either a single disulﬁde
bond such as bactenecins. A cyclic lipopeptide, polymyxin B (PMB),
has long been used as a model compound to deﬁne the mechanisms
by which AMPs kill bacteria and how bacteria develop resistance to
antimicrobial actions of AMPs.
The initial electrostatic interaction of the positively charged AMPs
with the negatively charged lipopolysaccharides of the outer leaﬂet of
the outer membrane is believed to initiate the self-promoted uptake
of AMPs in Gram-negative bacteria [13]. Subsequently, both electrostat-
ic and hydrophobic interactions between AMPs and the inner mem-
brane phospholipids are critical for AMP's antimicrobial activity that
disrupts membrane integrity. As the membrane–peptide complexes
are insoluble and non-crystalline, solid-state NMR studies of AMPs
[14] have been used to obtain structure, dynamics, orientation, and olig-
omeric states of AMPs in amembrane environment [15,16] as well in li-
popolysaccharide micelles [17–20]. These biochemical studies provide
important information about the mechanism of action of AMPs at mo-
lecular level. Further, recent studies suggested that AMPs are also able
to act on intracellular targets following their translocation across the
inner membrane either as a main mode of action or as additive effects
combining with membrane disruption [13,21]. Expression of AMPs is
widespread in many cell types. AMPs are constitutively produced by
phagocytic cells such as macrophages and neutrophils [6]. For example,
defensins have been shown to be the most abundant protein species in
neutrophils [22]. Mucosal epithelial cells also constitutively expressed
AMPs and AMP production can be further induced following exposure
to bacterial determinants [23]. AMPs can also be formed by proteolyticdigestion of larger cationic proteins such as lactoferricin, a proteolytic
cleaved product from the N-terminus of lactoferrin [24].
3. AMP resistance mechanisms in N. meningitidis
Following acquisition through close contact with a carrier, meningo-
cocci overcome clearance and other local speciﬁc and nonspeciﬁcmuco-
sal host defenses in order to colonize the upper respiratory mucosal
surfaces (e.g., the nasopharynx). Colonization of N. meningitidis may
also result in invasion of epithelial surfaces, access to the bloodstream
and the production of systemic and focal infections. As the only natural
reservoir of N. meningitidis is the human nasopharynx, meningococci
constantly encounter endogenous antimicrobial defense including anti-
microbial peptides during colonization and infection. Thus, it is not sur-
prising that meningococci have developed mechanisms for conferring
intrinsic and/or inducible resistance to the action of AMPs. AMP
resistance mechanisms have been well-characterized in various Gram
negative bacteria to include (i) efﬂux pumps that export AMP from
the periplasmic and intracellular compartments [25]; (ii) structural
modiﬁcations of lipopolysaccharide (LPS) and lipooligosaccharide
(LOS) to reduce interaction with AMPs; (iii) modulation of outer mem-
brane permeability to limit entry and/or enhance excretion of AMPs;
and (iv) proteases that degrade AMPs [26,27]. Here we summarize the
current knowledgeof AMP resistancemechanisms aswell as other char-
acteristics that inﬂuence AMP resistance inN. meningitidis (Fig. 1) in the
order of importance. The inducible effects of AMPs on some of these re-
sistance determinants will also be discussed.
3.1. Lipooligosaccharide (LOS)
Lipopolysaccharide (LPS) is themajor component of the outer leaﬂet
of the outermembrane of Gram-negative bacteria. Meningococcal LPS is
a lipooligosaccharide (LOS) that is structurally similar to LPS, but does
not have repeating O-antigens. Both LOS and LPS have a conserved
inner core region composed of heptose and 3-deoxy-D-manno-2-
octulosonic acid (KDO) attached to a lipid Amoiety. Themeningococcal
lipid A structure has a symmetrical distribution of acyl chain (C12 and
C14) attachments to the di-galactosamine backbone (Fig. 1) and thus
differs from that described for E. coliwith an asymmetrical distribution
of C14 and C16 acyl chains [28]. One of the best-characterized mecha-
nisms of AMP resistance is remodeling of LPS [29]. It is believed that
AMPs interacts with phosphorylated head groups of lipid A, andmodiﬁ-
cation of the lipid A head groups correlates with increased PMB
resistance. Such structural modiﬁcations that have been shown to
affect CAMP resistance include i) removal of the phosphate head groups
of the lipid A disaccharides [30,31]; (ii) modiﬁcations of lipid A head
groups by the addition of positively charged moieties, such as
aminoarabinose [32–35], glucosamine [36], galactosamine [37]
or phosphoethanolamine (PEA) [38,39]; and (iii) alteration in the de-
gree of lipid A acylation such as the formation of hepta-acylated lipid
A [40,41].
Among the different structural modiﬁcations of the lipid A head
group identiﬁed in Gram negative bacteria, only the PEA modiﬁcation
has been demonstrated in N. meningitidis. This is consistent with the
fact that meningococci only encodes the PEA transferase LptA [42] and
the gene cassette encoding the aminoarabinosemodiﬁcationmachinery
is absent in the meningococcal genomes. In contrast to the lipid A of
E. coli and Salmonella enterica, which may be modiﬁed by PEA after in-
duction by certain environmental conditions [38], meningococcal lipid
A is constitutively substituted with PEA [43,44], which is a key factor
that deﬁnes the intrinsic high level resistance of meningococci to PMB
[39]. An lptA mutation caused ~250 fold reduction in PMB resistance
to reach levels similar to those of E. coli. In comparison, anmtrmutation
that inactivates major efﬂux pumps in meningococci resulted in a 16-
fold reduction [39], demonstrating the LptA-mediated PEA decorations
of lipid A is vital to meningococcal resistance. Recently, a poly-T8 tract
Fig. 1. A schematic summary of cellular factors inﬂuencing antimicrobial peptide resistance in Neisseria meningitidis. AMPs can initiate the self-promoted uptake through electrostatic in-
teractions with negatively charged lipopolysaccharides of the outer membrane or through the secretin apparatus of type IV pili. The constitutive PEA modiﬁcation of lipid A head groups
reduces electrostatic interactions of AMPs with the cell envelop, while both capsule and bleb act to sequester AMPs from reaching the cell surface. The Mtr efﬂux pump can expel AMPs
from either periplasm or cytoplasm by active efﬂux, and the major outer membrane porin, PorB, also likely functions as an excretion channel.
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~10−5 in N. gonorrhoeae, and the frame shift resulted in truncated LptA
and PMB sensitivity [45]. Such a poly-T8 tract is also present in menin-
gococcal lptA, but it is as yet unknown whether it varies at a signiﬁcant
frequency. LptA is anchored to the periplasmic face of the cytoplasmic
membrane by a transmembrane domain and utilizes the phosphatidyl-
ethanolamine lipid as its substrate. The crystal structure of LptA soluble
domain was solved and shown to contain 5 disulﬁde bonds [46], sug-
gesting that LptA is stabilized by disulﬁde bonds. Indeed, the presence
of DsbA3, one of three DsbA proteins encoded in meningococci, sup-
ported LptA stability because lacking DsbA3 had a measurable decrease
in the amount of PEA decoration on lipid A head groups [47]. Further,
combinations of multiple dsbAmutations displayed an additive increase
in sensitivity to PMB, indicating that all three oxidoreductases were
needed for either LptA-dependent and/or independent pathways that
lead to PMB resistance [47]. The constitutive modiﬁcations aiming to
reduce negative charges in the LPS molecules appear to be a major
determinant of antimicrobial peptide resistance in several high AMP re-
sistant bacteria. In addition to N. meningitidis that utilizes constitutive
PEA modiﬁcation, Burkholderia sp. also constitutively produce LPS with
aminoarabinose substitution [48] and is resistant to AMPs at a level sim-
ilar to meningococci.
Additional structural features of lipid A contributing to PMB resis-
tance have been characterized. While O-antigens [49] and inner core
of LPS in Burkholderia cenocepacia [50] contribute to PMB resistance,
further truncation of the outer or inner core oligosaccharides in menin-
gococcal LOS, however, did not affect PMB susceptibility. An outermem-
brane localized acyltransferase PagP, which transfers palmitate from
phospholipid to lipid A to generate hepta-acylated lipid A, is important
for inducible AMP resistance in Salmonella and E. coli [40,51], indicatingthat increasing lipid A acylation is an AMP resistance mechanism [39].
Varying lipid A acylation patterns in LPS could result in different outer
membrane permeability and is a probable underlying AMP resistance
mechanism. Although this hepta-acylation mechanism is absent in
N.meningitidis, decreased acylation of lipid A indeed reduced AMP resis-
tance, correlating with the effect of varying degrees of lipid A acylation
onAMP resistance.Mutations in the late acyl transferases, lpxL1or lpxL2,
responsible for adding the acyloxyacyl laurate chains to the 2 and 2′ po-
sitions of lipid A [52], resulted in penta-acylated lipid A and reduced
PMB resistance [39]. Naturally occurring lpxL1mutations via different
insertion/deletion events have been identiﬁed inmany invasive menin-
gococcal clinical isolates [53]. The resulting underacylated lipid A was
shown to have low endotoxin activity with reduced proinﬂammatory
cytokine induction [53]. Such variants, although become less resistant
to AMPs, likely cause reduced AMP production, thus aiding meningo-
cocci to evade the innate immune system.
Finally, mutation in the ABC transporter system (lptH) responsible
for LOS export [54] was also identiﬁed in a transposon mutagenesis
study to further reduce AMP resistance [39]. A lptH mutant contained
signiﬁcantly lower cellular levels of LOS and released high levels of
proteins into the medium [54]. The apparent leakiness of the lptHmu-
tant, as indicated by their enhanced sensitivity toward vancomycin
[54], likely allows AMP to reach its target membrane more readily,
leading to higher PMB sensitivity.
3.2. Efﬂux pumps
Several efﬂux pumps including FarA/B [55]. MacA/B [56], NorM [57]
andMtrC/D/E [58], have been largely characterized in N. gonorrhoeae
to mediate resistance toward various antimicrobial agents and
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Mtr pump is formed by the outer membrane MtrE, the membrane fu-
sion protein MtrC and the inner membrane protein MtrD and belongs
to the resistance-nodulation-division (RND) efﬂux pump family. Only
theMtr pumpwas shown tomodulate gonococcal susceptibility to sev-
eral structurally unrelated AMPs, such as the β-sheet peptide PG-1 and
the α-helical peptide LL-37 [60]. However, human defensin HNP-2 is
not a substrate of the gonococcal Mtr pump as anmtrmutant is equally
resistance to this AMP [60]. The contribution of Mtr efﬂux pumps to
AMP resistance in N. meningitidis has been clearly demonstrated as we
have shown that the meningococcal Mtr pump decreases susceptibility
to PMB, LL-37, and PG-1 [39]. In a transposon random mutagenesis
screen, more than half of the PMB sensitive mutants are due to various
insertions within themtrCDE operon, supporting the importance of Mtr
pump in AMP resistance [39]. These mutants displayed ~16-fold reduc-
tion in PMB resistance.
Meningococci, in general, exhibit ~5-fold higher PMB resistance
compared to gonococci, partially due to genetic polymorphisms of the
mtr locus between the two species. In N. gonorrhoeae the Mtr efﬂux
pump is regulated by a divergently transcribed repressor, MtrR, and is
inducible by its substrates through a transcriptional activator, MtrA
[61] that is not universally present in all gonococcal strains. However,
inN. meningitidis, theMtr pump is not inducible and is highly expressed
due to various mutations in themtrR coding sequence [62]. In addition,
there are polymorphisms within the meningococcal mtr promoter re-
gion, including an insertion of a ~150-bp Correia element or an IS1301
element together with the Correia element. These genetic variations
within the promoter region showed different promoter activities [62]
that lead to varied Mtr pump expression levels.
3.3. Outer membrane proteins
As restricting access of AMPs to its cytoplasmic membrane targets
confers resistance, one logical strategy in Gram negative bacteria is to
reduce outer membrane permeability. In addition to LPS/LOS mediated
outer membrane permeability changes described above, outer mem-
brane porins may function as entry/excretion channels for AMPs and
thus inﬂuence the levels of AMP crossing the outer membrane barrier.
Indeed, PorB, one of the two major porins of N. meningitidis, affects
AMP resistance because a porB mutant is 16-fold more sensitive to
PMB [39]. This phenotype differs from the observation that a porBmu-
tation increased resistances to several antibiotics such as ciproﬂoxacin
and cephalosporins [63]. Since the porBmutant is not more susceptible
to other Mtr efﬂux pump substrates, the increased PMB sensitivity was
not caused by a decrease in the efﬂux function or levels of theMtr pump.
A general outermembrane permeability increase in the absence of PorB
is also not likely as this would correlate with an increase in antibiotic
sensitivity. Thus, the increased AMP sensitivity of the porB mutant
suggests that excretion of AMPs by PorB is possibly an active AMP resis-
tance mechanism.
On the other hand, the pilin secretion apparatus may act as an entry
point for AMPs. A transposon screening for enhanced PMB resistance in
N. meningitidis identiﬁed ﬁve mutants that all mapped in the pilMNOPQ
locus [39], predicted to encode proteins involved in type IV pilus biogen-
esis. A mutant form of the pilus secretin protein PilQ in N. gonorrhoeae
that allows increased entry of antimicrobial compounds has also been
identiﬁed [64].
Outer membrane proteins may also play a role in sequestering AMP
from reaching its targets. Two such examples have been characterized
in N. meningitidis. First, fHBP-deﬁcient strains are more sensitive to kill-
ing by LL-37 [65]. Factor H-binding protein (fHBP), an outer membrane
lipoprotein, enables innate immune system evasion ofN.meningitidis by
binding to the inhibitor of the complement alternative pathway, factor
H, and is one of the recombinant vaccine antigens present in serogroup
B meningococcal vaccine [66]. The fHBP protein does not have proteo-
lytic activity against LL-37, does not affect efﬂux of LL-37 and nodecreased outer membrane stability is detected in the mutant [65]. As
the mutant is more resistant to killing by LL-37 in the presence of 2%
NaCl and low pH, it was suggested that fHBP likelymediate electrostatic
interactionwith LL-37 as a sequestrationmechanism to prevent contact
with the cell membrane. Second, lactoferrin binding protein B (LbpB), a
surface-exposed membrane bound lipoprotein, was shown to provide
protection against lactoferricin [67] and the cathelicidin related antimi-
crobial peptide (mCRAMP), but not against LL37 [68]. LbpB works to-
gether with LbpA to constitute host-speciﬁc lactoferrin receptors and
can be selectively released from the bacterial surface [69]. The negative-
ly charged amino acid clusters of LbpB are responsible for the protective
effect against lactoferricin [67].
3.4. Capsular polysaccharides
N. meningitidis is encapsulated and expresses one of the 12 capsular
polysaccharide (CPS) structures (e.g. serogroup). Capsule is the most
critical meningococcal virulence determinant during bacteremia, men-
ingitis and other invasive meningococcal disease, as it imparts
antiphagocytic and antibactericidal properties to the meningococcus
[43,70–72]. An additional mechanism by which the capsule protects
meningococci is to provide increased resistance to AMPs as
unencapsulated serogroup B (α-2, 8-polysialic acid capsule) strains
were more susceptible than encapsulated meningococci to defensins
(β defensin 1&2, HNP-1&2) cathelicidins (LL-37, CRAMP, CRAMP-18),
protegrin PG-1, and polymyxin B [73]. Similarly, a contribution from
capsule to LL-37 resistance was shown in an encapsulated serogroup C
strain that expresses α-2, 9-polysialic acid capsule [74]. Further,
this study showed that after exposure to nonlethal concentrations of
LL-37, higher proportion of unencapsulated meningococci accumulated
LL-37 on the surface compared to the encapsulated wild-type strain
[74], suggesting that CPS reduces the binding of LL-37 to the bacterial
surface. All disease-causing meningococcal serogroups express nega-
tively charged capsular polysaccharides and the nonproductive electro-
static interaction between CPS and AMP could serve as a sequestering
mechanism to limit AMP reaching its targets. Thus, CPS acts as a shield
to reduce the binding of AMPs to bacterial surface. As a correlation,
CPS-mediated AMP resistance in Klebsiella pneumoniae was shown to
be unrelated to the CPS chemical composition but was dependent on
the amount of CPS expressed [75].
3.5. Bleb and bioﬁlm
Meningococci are characterized by frequent vesiculation (blebing)
of the outermembrane [76] that appears to contribute to rapid initiation
of the inﬂammatory cascades of meningococcal diseases. Blebs, which
contain DNA, outer membrane proteins and LOS, have been shown to
be major constituents of the bioﬁlm matrix and the ability to produce
blebs shown to be crucial to bioﬁlm formation in N. gonorrhoeae [77].
Contributions of bioﬁlm to AMP resistance have been characterized in
other bacteria [78] and likely also play a role in meningococcal AMP re-
sistance. N. meningitidis has been shown to form bioﬁlm on abiotic sur-
faces as well as on epithelial cells [79–81]. Blebing may potentially
function as another sequestering mechanism of AMP evasion through
the unproductive electrostatic interactions between LOS/DNA within
blebs and AMPs, either in the presence or absence of bioﬁlm.
4. Response to AMP exposure in N. meningitidis
Without constitutive and intrinsically high levels of resistance, bac-
teria targeted by AMPs have to be able to detect and respond to AMPs
and the efﬁciency of these processes are important for the survival of
bacteria in the host [82]. Well-characterized response mechanisms are
the PhoP/PhoQ and PmrA/PmrB two-component system-mediated
inducible resistance to AMPs that resulted in modiﬁcations of lipid A
head groups by aminoarabinose and PEA and formation of hepta-
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lipid A head groups and the Mtr efﬂux pump were constitutively
expressed at high levels likely reduces the dependence on inducible
AMP resistance in N. meningitidis. However, inducible responses to
AMP exposure in N. meningitidis have been shown in several studies. A
mutation in the MisR/MisS two-component system caused a 2-fold re-
duction in lptA expression [44]. Although no quantitative changes in
PEAmodiﬁcation levels of lipid Awere detected, themisR/misSmutants
are more sensitive to PMB, suggesting that other genes controlled by
this two-component system are involved in AMP resistance. Exposures
to PG-1 and LL-37 at concentrations close to the MIC elicit an increase
(~1.5–2 fold) on mtrCDE transcript levels in N. meningitidis [73]. As
these two AMPs are not structurally related, the up-regulation is unlike-
ly promoted by sensing speciﬁc AMPs, but potentially by sensing
perturbation of the inner and/or outer membrane. Another study
showed an up-regulation of mtrD upon a 30-minute exposure to
sublethal dose of LL-37 [74]. Interestingly, exposure to LL-37 also further
induces expression of CPS genes in this study [74]. A global tran-
scriptome study performed by treating a serogroup B meningococcal
strain with a sublethal concentration of CRAMP, a mouse LL-37 homo-
log, for 1 h found a total of 21 genes being differentially expressed great-
er than 2-fold [85]. Up-regulated genes encode proteins involved cell
envelope processing such as pilin glycosylation; while genes involved
in energy metabolism are down-regulated. Among many affected
geneswith unknown functions [85], two encoding conserved hypothet-
ical proteins were further characterized. A mutation in either NMB0741
or NMB1828 caused ~3-log lower bacteremia in an adult mouse model
of infection and the NMB1828 protein binds LL-37 in vitro [85].
5. Summary
Considerable progress has been made in identiﬁcation of the
molecular basis of antimicrobial peptide resistance mechanisms in
N. meningitidis and many other bacterial pathogens. Resistance to anti-
microbial peptides is multifactorial as pathogens use multiple mecha-
nisms to resist AMPs. The contribution and the relative importance of
each resistance mechanism vary in different bacterial species.
N. meningitidis utilizes several efﬁcient strategies to defend against
AMPs. The critical mechanism is constitutive LOS modiﬁcation by PEA,
which is further enhanced by efﬁcient excretion of AMPs by efﬂux
pumps. Other resistancemechanisms, such as CPS and outer membrane
protein expression, appear to play a more limited role but contribute to
the total high level of resistance. As AMPs are actively being explored as
a new class of antimicrobial therapeutics [86,87], expanding our under-
standing of AMP resistance mechanisms in bacterial pathogens is
essential.
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